Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic rivaroxaban 10 mg vs Xarelto in healthy Thai volunteers under fasting conditions
TCTR20211111004Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by International Bio Service. Primary endpoint: Bioequivalence based on pharmacokinetic parameters. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on TCTR20211111004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211111004.